Stable Biodegradable Polymers for Delivery of Both Polar and Non-Polar Drugs. Phase I
Abstract
The objective of this project is to develop improved dose forms for the delivery of pain management agents. Given a military scenario where rapid deployment of Special Operations Forces demands effective medical resources, the need for therapeutic pain management tools is obvious. Pain relief is critical in maintaining the ability of the field soldier to defend and protect himself particularly in cases where mobilization is not imminent. Our development work on a pain management system, of which a hydromorphone(HM)/ poly(lactide-co-glycolide) (PLGA) delivery system is a part, addresses battlefield treatment with respect to personnel maintenance. A long acting HM/PLGA implant, easily implanted via a loaded trocar, could provide systemic relief from pain at the time of injury. Phase I work included in vitro and in vivo (mice) testing of four HM/PLGA matrices, HM at 25% and 50% loading in each of two PLGAs (85:15 and 50:50). In vitro release data and mouse tail flick data permitted selection of a system for further development - a 50:50 PLGA containing 25% HM. Data support its use as a 10 day pain management system for combat casualty care.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1996
- Accession Number
- ADB222994
Entities
People
- Joseph D. Gresser